For millions of people who manage diabetes with injected insulin, the daily needle is a fixed part of life. A new generation of long-acting insulins aims to change that by working for a full week from a single injection, potentially cutting the number of basal insulin shots from more than 300 a year to about 52. Late-stage clinical trials have reported that these once-weekly formulations can control blood sugar about as well as daily insulin, and the shift could ease one of the most burdensome aspects of treatment.
How once-weekly insulin works
Insulin is the hormone that allows the body’s cells to take up glucose from the blood for energy. People with type 1 diabetes make little or no insulin and must replace it, while many with type 2 diabetes eventually need it as their own production declines. Treatment typically combines a long-acting “basal” insulin that provides a steady background level with faster-acting doses around meals. The National Institute of Diabetes and Digestive and Kidney Diseases describes how these different insulin types are used together to keep blood sugar in a target range.
The once-weekly insulins are basal insulins engineered to last far longer in the body. Developers achieve that by modifying the insulin molecule so it binds reversibly to proteins in the blood, most often albumin, creating a reservoir that releases the hormone slowly and steadily over about seven days. The two most advanced candidates in this class are insulin icodec and insulin efsitora alfa, each the subject of large trial programs testing whether a single weekly injection can match daily basal insulin.
What the trials have shown
The clinical evidence has centered on whether weekly insulin controls blood sugar as effectively as the daily standard, measured chiefly by hemoglobin A1c, a marker of average glucose over roughly three months. Across multiple large trials in type 2 diabetes, the weekly formulations generally achieved A1c reductions comparable to daily basal insulin, meeting the bar of non-inferiority that regulators require. The American Diabetes Association, which sets widely followed treatment standards, publishes guidance on how insulin and other injectable therapies fit into diabetes care.
The picture has been more nuanced in type 1 diabetes. Because people with type 1 make no insulin of their own, their blood sugar is more sensitive to dosing, and some trials of weekly insulin in this group have flagged concerns about the balance of glucose control against the risk of hypoglycemia, or dangerously low blood sugar. That has led developers and regulators to focus initial use primarily on type 2 diabetes, where a stable background insulin level is often easier to maintain.
The appeal of fewer injections
The central promise of weekly insulin is a dramatic reduction in injection burden. Fewer injections can improve what clinicians call adherence, the degree to which people actually take medication as prescribed. Missed or skipped doses are a well-documented problem in diabetes care, and the prospect of remembering one injection a week rather than one a day could help some patients maintain more consistent treatment. The Centers for Disease Control and Prevention notes that diabetes affects a large and growing share of the population, so even incremental improvements in adherence could have broad public-health effects.
A weekly schedule may be especially valuable in specific settings. For older adults who depend on caregivers or visiting nurses to administer injections, reducing the frequency could lower cost and logistical strain. For people newly starting insulin, particularly those with type 2 diabetes who resist beginning daily injections, a weekly option might make the transition more acceptable.
The trade-offs and open questions
A longer-acting drug also carries a longer-lasting risk. If a dose is too high or circumstances change, such as reduced food intake or increased activity, the elevated insulin level cannot be quickly withdrawn, and the effect persists for days. Managing hypoglycemia therefore becomes a more deliberate exercise with weekly insulin than with daily formulations that clear the body faster. Dosing at the start of therapy and when adjusting doses requires particular care.
Regulatory status varies by drug and by country, and approval in one market does not guarantee it elsewhere. Coverage of ongoing diabetes research, including summaries compiled by outlets such as the health section of ScienceDaily, has tracked the weekly insulins through their trial programs and regulatory reviews. Cost and insurance coverage will also shape how widely the option is used, since a novel formulation may be priced above established daily insulins.
A potential shift in routine diabetes care
If weekly basal insulins become widely available and affordable, they could represent one of the more practical changes in diabetes management in years, not because they control blood sugar better than existing insulins, but because they make sustained control easier to achieve. The scientific question of efficacy has largely been answered in the affirmative for type 2 diabetes; the remaining questions are about safety in specific populations, appropriate dosing and access.
For now, daily injections remain the standard for most insulin users, and any switch would be a decision made with a clinician based on individual circumstances. But the arrival of insulin that works for a full week marks a meaningful step toward reducing the relentless daily rhythm that has defined insulin therapy since its introduction more than a century ago.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
